Durham, NC – Registration is now open for the Society for Translational Oncology (STO) 2015 Chabner Colloquium: Collaboration in Cancer Trials. The continuing medical education (CME) symposium is jointly provided by The Massachusetts General Hospital Cancer Center and STO, in partnership with The Oncologist, STO’s official journal. It will be held October 26 -27, 2015 at The Liberty Hotel in Boston, Massachusetts.
The 2015 Chabner Colloquium will provide updates on the most promising targets for the development of new cancer treatments. Physician-scientists, industry professionals, and others interested in learning about advances in cancer biology leading to new approaches in clinical practice are invited to view the agenda, confirmed faculty, and register online at http://bit.ly/chabner2015.
Offered for the fifth year, the 2015 Chabner Colloquium includes presentations on emerging molecular targets for cancer treatments—with a focus on potentially productive opportunities for collaboration between academia and industry. Physician-scientists from leading U.S. research centers will address work in progress in a broad variety of topics in cancer therapeutics. Invited speakers hail from renowned institutions such as The Massachusetts General Hospital Cancer Center, the Broad Institute of MIT and Harvard, the Dana-Farber Cancer Institute, The Salk Institute for Biological Studies, and the US Food and Drug Administration.
The meeting is named for Dr. Bruce A. Chabner, Allen Distinguished Investigator, Clinical Director, Emeritus at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist. Dr. Chabner designs and leads this annual program. Dr. Chabner states, “It’s a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead.”
On Monday, October 26th, the session topics include lectures on breast cancer biology, tumor quiescence, new approaches to immunotherapy, and the genomics of metastatic tumors to the central nervous system.
The day concludes with a forum of fellows from Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute sharing their recent work.
On Tuesday, October 27th, the session topics include lectures on strategies for and promising results from ongoing Phase I trials, and accelerated pathways for drug approval.
STO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This two-day CME symposium will be designated for a maximum of 9 AMA PRA Category 1 Credit(s)™.
For more information contact STO at (919) 433-0489 or CMEadmin@sto-online.org.
###
About the Society for Translational Oncology: STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: www.sto-online.org.
About The Oncologist: Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its twentieth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: www.theoncologist.com.
About The Massachusetts General Hospital Cancer Center: An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States. Known for providing customized, innovative treatments and compassionate care to both adults and children, the Massachusetts General Hospital Cancer Center comprises more than 25 fully integrated, multidisciplinary clinical programs and a vast array of support and educational services. The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.
For more information, contact:
Jen Homan, Program Manager, STO
(919) 433-0489
jen.homan@sto-online.org
Help employers find you! Check out all the jobs and post your resume.
